Zák A, Zeman M, Vítková D
IV. interní klinika 1, Praha.
Cas Lek Cesk. 1994 Dec 22;133(24):755-8.
Hypertriglyceridaemia associated with low HDL-concentrations is considered an independent risk factor of ischaemic heart disease. The drug of choice in this disorder is nicotinic acid. The aim of the presented work was to compare the hypolipidaemic effect of fish oils rich in omega-3 fatty acids (Activepa 30-TGR, Hydromartens, Norway) with a nicotinic acid derivative, acipimox (Olbetam, Farmitalia Carlo Erba, Italy).
The preparations were administered for a three-week period to two groups of patients with hypertriglyceridaemia and low HDL cholesterol levels. The groups had comparable body weights and baseline parameters of lipid metabolism. In the group treated with Olbetam (750 mg/day), 17x hyperlipoproteinaemia type IV and 6x IIB) after treatment significant changes of the following parameters were recorded: triglycerides (-18%; P < 0.001), HDL cholesterol (+19%; P < 0.01), HDL2 and HDL3 cholesterol (+33%; +14%; P < 0.001, P < 0.01), apo B (+25%; P < 0.01), apo A-I (+7%; P < 0.01), ratio of apoB/A-I (+17%; P < 0.01). Furthermore, there was s drop of the atherogenic index (total cholesterol/HDL cholesterol) by 22% (P < 0.001). In the group of subjects (17x type IV and 8x type IIB) whose diet was enriched with omega-3 fatty acids (3.5 g/day), the following parameters changed significantly: triglycerides (-44%; P < 0.001), the atherogenic index (-23%; P < 0.001), HDL cholesterol (+11%, P < 0.01), HDL2 and HDL3 cholesterol (+13%, +17%; P < 0.01, P < 0.05). Changes of apo B, apo A-I concentrations and their ratios were not significant. Comparison of the effect of the two preparations on the investigated parameters revealed a more marked rise of the HDL cholesterol (P < 0.05), apo B (P < 0.01) concentrations and the apo B/-A-I ratio (P < 0.05) during Olbetam treatment. As to the action of the two preparations on further investigated parameters (total and LDL-cholesterol), no significant differences found.
The assembled results indicate that enrichment of the diet with fish oil rich in omega-3 fatty acids has a hypolipidaemic effect comparable to acipimox. It is thus feasible to use fish oils as a drug of first choice in the treatment of hypertriglyceridaemia associated with a reduction of HDL cholesterol concentration.
高甘油三酯血症伴低高密度脂蛋白(HDL)浓度被认为是缺血性心脏病的独立危险因素。治疗这种疾病的首选药物是烟酸。本研究的目的是比较富含ω-3脂肪酸的鱼油(Activepa 30-TGR,挪威Hydromartens公司)与烟酸衍生物阿西莫司(Olbetam,意大利Farmitalia Carlo Erba公司)的降血脂效果。
将这两种制剂对两组高甘油三酯血症和低HDL胆固醇水平的患者进行为期三周的给药治疗。两组患者的体重和脂质代谢基线参数具有可比性。在用Olbetam(750毫克/天)治疗的组中(17例IV型和6例IIB型高脂蛋白血症),治疗后记录到以下参数有显著变化:甘油三酯(-18%;P<0.001),HDL胆固醇(+19%;P<0.01),HDL2和HDL3胆固醇(+33%;+14%;P<0.001,P<0.01),载脂蛋白B(+25%;P<0.01),载脂蛋白A-I(+7%;P<0.01),载脂蛋白B/A-I比值(+17%;P<0.01)。此外,致动脉粥样硬化指数(总胆固醇/HDL胆固醇)下降了22%(P<0.001)。在饮食中富含ω-3脂肪酸(3.5克/天)的受试者组中(17例IV型和8例IIB型),以下参数有显著变化:甘油三酯(-44%;P<0.001),致动脉粥样硬化指数(-23%;P<0.001),HDL胆固醇(+11%,P<0.01),HDL2和HDL3胆固醇(+13%,+17%;P<0.01,P<0.05)。载脂蛋白B、载脂蛋白A-I浓度及其比值的变化不显著。比较两种制剂对所研究参数的影响发现,在Olbetam治疗期间,HDL胆固醇(P<0.05)、载脂蛋白B(P<0.01)浓度和载脂蛋白B/A-I比值(P<0.05)升高更为明显。至于两种制剂对进一步研究的参数(总胆固醇和低密度脂蛋白胆固醇)的作用,未发现显著差异。
汇总结果表明,饮食中富含ω-3脂肪酸的鱼油具有与阿西莫司相当的降血脂效果。因此,在治疗伴有HDL胆固醇浓度降低的高甘油三酯血症时,将鱼油作为首选药物是可行的。